The UK regulator, the MHRA, is running a pilot to test out the practicalities of creating “target development profiles” that will guide the development of new medicines under its innovative medicines licensing pathway to be introduced in January next year.
The new integrated pathway will pull together expertise from across the Medicines and Healthcare products Regulatory Agency and from partners in the wider health care system, including NICE and the SMC, the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?